45 results
8-K
PSTX
Poseida Therapeutics Inc
1 May 24
Entry into a Material Definitive Agreement
9:07am
following receipt of the applicable IND-enabling data package, and (iii) an exclusive license under certain Company intellectual property to manufacture … the generation of an IND-enabling data package and Xyphos is obligated to reimburse the Company for FTE costs and expenses incurred by the Company
DEFA14A
PSTX
Poseida Therapeutics Inc
25 Apr 24
Additional proxy soliciting materials
4:08pm
or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package
DEFA14A
t4nnsso o8i
26 Apr 23
Additional proxy soliciting materials
4:10pm
8-K
EX-1.1
5hrmvekw ma
4 Aug 22
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
4:57pm
DEFA14A
2tf0igvo
27 Apr 22
Additional proxy soliciting materials
4:38pm